We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CSTM:NYSEConstellium SE Analysis

Data as of 2026-09-23 - not real-time

$24.96

Latest Price

9/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind Constellium SE is neutral at $24.96, with no clear ordering between short and long averages. It has lost 15.0% over the past 30 days. Relative strength is 35.8 — approaching oversold — and the MACD signal is bearish. The recent range runs from support at $24.37 up to resistance at $28.10.
On valuation the read is undervalued — an earnings multiple of 6.5, absent a reliable peer benchmark. Analyst price targets sit 47.1% above the current price. Revenue is growing at 30.7% on a 5.7% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 36.3%, a beta of 1.89 and a maximum drawdown of 31.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons diverge: hold near-term but buy on a long view, at 4/10 conviction over the longer horizon.

Top Market Events

Here is how Constellium CSTM and Distribution Solutions Group DSGR have performed compared to their sector so far this...PARIS, April 15, 2026 GLOBE NEWSWIRE -- Constellium SE NYSE: CSTM will host a conference call and webcast on Wednesday,...Kalkine Media4dWhy Are Traders Talking About Constellium CSTM ?

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 27.14
  • MACD momentum is negative
  • 30-day price change of -15.0%

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Trading below the 200-day average of 27.14
  • Analyst targets imply +47.1% versus the current price
  • MACD momentum is negative

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • Analyst targets imply +47.1% versus the current price
  • Revenue growth of +30.7%
  • P/E ratio of 6.5

Key Metrics & Analysis

Financial Health

Revenue Growth30.70%
Profit Margin5.69%
P/E Ratio6.5
ROE53.09%
ROA9.93%
Debt/Equity153.35
P/B Ratio2.7
Op. Cash Flow$551.0M
Free Cash Flow$53.6M

Technical Analysis

TrendNeutral
RSI35.8
Support$24.37
Resistance$28.10
MA 20$26.40
MA 50$27.77
MA 200$27.14
MACDBearish
VolumeIncreasing
Fear & Greed Index94.29

Valuation

Fair Value$0.29
Target Price$36.73
Upside/Downside47.14%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.89
Volatility36.33%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.